Skip to main content
Clinical Trials/JPRN-jRCT1030210419
JPRN-jRCT1030210419
Not yet recruiting
未知

Study on the effect of disease modifiers on pain, fatigue and quality of life (QOL) in patients with neuromyelitis optica spectrum disorder (NMOSD)

Kazuhiro Ishii0 sites30 target enrollmentNovember 10, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
euromyelitis Optica Spectrum Disorders
Sponsor
Kazuhiro Ishii
Enrollment
30
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 10, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Kazuhiro Ishii

Eligibility Criteria

Inclusion Criteria

  • The NMOSD diagnosis follows the diagnostic criteria of Wingerchuk et al. (Wingerchuk DM 2007, 2015\). The subjects were patients who were diagnosed, treated, or newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD) at our hospital from September 2020 to March 31, 2022\. Patients who started administration of oral steroid humanized monoclonal antibody (Satralizumab, etc.) as a therapeutic intervention.

Exclusion Criteria

  • Minors (under 20 years old)

Outcomes

Primary Outcomes

Not specified

Similar Trials